ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

The Bcl-2 apoptotic switch in cancer development and therapy

Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,178 · see citing works

GenePattern 2.0

Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,035 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Acute lymphoblastic leukaemia

Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564 · see citing works

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130 · see citing works

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012 · see citing works

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 833 · see citing works

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734 · see citing works

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588 · see citing works

Proposals for immunological classification of acute leukemias.

van Dongen, J. J. M. (1995) · PubMed · Cited by 543 · see citing works

Proposals for the immunological classification of acute leukemias.

Paietta, E. M. (1995) · PubMed · Cited by 503 · see citing works

The molecular basis of T cell acute lymphoblastic leukemia

Vlierberghe, P. V., & Ferrando, A. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61269 · Cited by 489 · see citing works

Bcl-2 family proteins are essential for platelet survival

Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427 · see citing works

HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL)

Soulier, J., Clappier, E., Cayuela, J., Régnault, A., García-Peydró, M., Dombret, H., Baruchel, A., Toribio, M. L., & Sigaux, F. (2005) · Blood · doi:10.1182/blood-2004-10-3900 · Cited by 382 · see citing works

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

Homminga, I., Pieters, R., Langerak, A., de Rooi, J. D., Stubbs, A., Verstegen, M., Vuerhard, M. J., Buijs-Gladdines, J., Kooi, C., Klous, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.008 · Cited by 381 · see citing works

Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience

Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., Cohen, H. J., Sallan, S. E., & Asselin, B. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.116 · Cited by 346 · see citing works

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

Touzeau, C., Dousset, C., Gouill, S. L., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat‐Deceunynck, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 290 · see citing works

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J. A., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B. L., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 276 · see citing works

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

Vaillant, F., Mérino, D., Lee, L., Breslin, K. A., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 275 · see citing works

Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission

Barrett, A. J., Horowitz, M. M., Pollock, B. H., Zhang, M., Bortin, M. M., Buchanan, G. R., Camitta, B. M., Ochs, J. J., Graham‐Pole, J., Rowlings, P. A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311902 · Cited by 235 · see citing works

The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal

McCormack, M. P., Young, L. F., Vasudevan, S., de Graaf, C. A., Codrington, R., Rabbitts, T. H., Jane, S. M., & Curtis, D. J. (2010) · Science · doi:10.1126/science.1182378 · Cited by 231 · see citing works

Decoding and unlocking the BCL-2 dependency of cancer cells

Juin, P. P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3538 · Cited by 231 · see citing works

The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia

Vlierberghe, P. V., van Grotel, M., Tchinda, J., Lee, C., Beverloo, H. B., van der Spek, P. J., Stubbs, A., Cools, J., Nagata, K., Fornerod, M. W. J., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111872 · Cited by 226 · see citing works

ETV6 mutations in early immature human T cell leukemias

Vlierberghe, P. V., Ambesi‐Impiombato, A., Pérez-García, A., Haydu, J. E., Rigo, I., Hadler, M., Tosello, V., Gatta, G. D., Paietta, E. M., Racevskis, J., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20112239 · Cited by 208 · see citing works

Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse

Clappier, E., Gerby, B., Sigaux, F., Delord, M., Touzri, F., Hernandez, L., Ballerini, P. F., Baruchel, A., Pflumio, F., & Soulier, J. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110105 · Cited by 203 · see citing works

ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

Vandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 194 · see citing works

Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15

Inukai, T., Kiyokawa, N., Campana, D., Coustan‐Smith, E., Kikuchi, A., Kobayashi, M., Takahashi, H., Koh, K., Manabe, A., Kumagai, M., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08955.x · Cited by 162 · see citing works

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo

Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., Lock, R. B., & Reynolds, C. P. (2007) · Blood · doi:10.1182/blood-2007-03-080325 · Cited by 157 · see citing works

Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia

Vlierberghe, P. V., Ambesi‐Impiombato, A., Keersmaecker, K. D., Hadler, M., Paietta, E. M., Tallman, M. S., Rowe, J. M., Forné, C., Rué, M., & Ferrando, A. A. (2013) · Blood · doi:10.1182/blood-2013-03-491092 · Cited by 153 · see citing works

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

Niu, X., Wang, G., Wang, Y., Caldwell, J. T., Edwards, H. J., Xie, C., Taub, J. W., Li, C., Lin, H., & Ge, Y. (2014) · Leukemia · doi:10.1038/leu.2014.72 · Cited by 127 · see citing works

ABT ‐199 selectively inhibits BCL 2 but not BCL 2 L 1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets

Vogler, M., Dinsdale, D. D., Dyer, M. J. S., & Cohen, G. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12457 · Cited by 105 · see citing works

T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.

Larson, R. C., Fisch, P., Larson, T., Lavenir, I., Langford, T., King, G., & Rabbitts, T. H. (1994) · PubMed · Cited by 95 · see citing works

The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.

Larson, R. C., Osada, H., Ta, L., Lavenir, I., & Rabbitts, T. H. (1995) · PubMed · Cited by 94 · see citing works

Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors

Zuurbier, L. C., Gutiérrez, A., Mullighan, C. G., Canté-Barrett, K., Gevaert, O., de Rooi, J., Li, Y., Smits, W. K., Buijs-Gladdines, J. G. C. A. M., Sonneveld, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090233 · Cited by 89 · see citing works

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

Suryani, S., Carol, H., Chonghaile, T. N., Frismantas, V., Sarmah, C. K., High, L. M., Bornhauser, B. C., Cowley, M. J., Szymanska, B., Evans, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0259 · Cited by 86 · see citing works

Notch Signaling During Human T cell Development

Taghon, T., Waegemans, E., & de Walle, I. V. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_230 · Cited by 58 · see citing works

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

Anderson, N. M., Harrold, I., Mansour, M. R., Sanda, T., McKeown, M. R., Nagykary, N., Bradner, J. E., Zhang, G. L., Look, A. T., & Feng, H. (2013) · Leukemia · doi:10.1038/leu.2013.377 · Cited by 52 · see citing works

SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL

Abdelali, R. B., Roggy, A., Leguay, T., Cieślak, A., Renneville, A., Touzart, A., Banos, A., Randriamalala, E., Caillot, D., Lioure, B., et al. (2014) · Blood · doi:10.1182/blood-2013-08-521518 · Cited by 50 · see citing works

BCL-2 Inhibitor Yields High Response in CLL and SLL

(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2013-178 · Cited by 15 · see citing works

The genetics and mechanisms of T cell acute lymphoblastic leukaemia

Belver, L., & Ferrando, A. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.63 · Cited by 445 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Jain, N., Lamb, A. V., O'Brien, S. M., Ravandi, F., Konopleva, M. Y., Jabbour, E. J., Zuo, Z., Jorgensen, J. L., Lin, P., Pierce, S. A., et al. (2016) · Blood · doi:10.1182/blood-2015-08-661702 · Cited by 354 · see citing works

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 282 · see citing works

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Frismantas, V., Dobay, M. P., Rinaldi, A. M., Tchinda, J., Dunn, S. H., Kunz, J. B., Richter‐Pechańska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 260 · see citing works

Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Fischer, U., Förster, M., Rinaldi, A. M., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B. C., Gombert, M., Kratsch, C., Stütz, A. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3362 · Cited by 258 · see citing works

Venetoclax: First Global Approval

Deeks, E. D. (2016) · Drugs · doi:10.1007/s40265-016-0596-x · Cited by 240 · see citing works

Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia

Inaba, H., & Pui, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091926 · Cited by 256 · see citing works

How I treat T-cell acute lymphoblastic leukemia in adults

Litzow, M. R., & Ferrando, A. A. (2015) · Blood · doi:10.1182/blood-2014-10-551895 · Cited by 227 · see citing works

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Zhang, H., Nakauchi, Y., Köhnke, T., Stafford, M., Bottomly, D., Thomas, R., Wilmot, B., McWeeney, S. K., Majeti, R., & Tyner, J. W. (2020) · Nature Cancer · doi:10.1038/s43018-020-0103-x · Cited by 207 · see citing works

Acute lymphoblastic leukaemia

Pagliaro, L., Chen, S., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Zhu, C. H., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 197 · see citing works

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A. K., Kurmasheva, R. T., Billups, C. A., Erickson, S. W., Guo, Y., Houghton, P. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707414 · Cited by 174 · see citing works

Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment

Correia, C., Lee, S. H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 168 · see citing works

Physiological and Pharmacological Control of BAK, BAX, and Beyond

Luna-Vargas, M. P. A., & Chipuk, J. E. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.07.002 · Cited by 142 · see citing works

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies

Cordo’, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0093 · Cited by 143 · see citing works

Precision medicine in acute lymphoblastic leukemia

Pui, C. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0759-8 · Cited by 132 · see citing works

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

Li, Z., He, S., & Look, A. T. (2018) · Leukemia · doi:10.1038/s41375-018-0201-2 · Cited by 132 · see citing works

A Novel l -Asparaginase with low l -Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo

Nguyen, H. A. T., Su, Y., Zhang, J. Y., Antanasijevic, A., Caffrey, M. S., Schalk, A. M., Liu, L., Rondelli, D., Oh, A. L., Mahmud, D. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2106 · Cited by 130 · see citing works

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Richard‐Carpentier, G., Jabbour, E. J., Short, N. J., Rausch, C. R., Savoy, J. M., Bose, P., Yilmaz, M. E., Jain, N., Borthakur, G. M., Ohanian, M. N., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.608 · Cited by 129 · see citing works

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126 · see citing works

UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemiaPreprint

Benyoucef, A., Palii, C. G., Wang, C., Porter, C. J., Chu, A., Dai, F., Tremblay, V., Rakopoulos, P., Singh, K., Huang, S., et al. (2016) · Genes & Development · doi:10.1101/gad.276790.115 · Cited by 126 · see citing works

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL ‐2 family members

Opferman, J. T. (2015) · FEBS Journal · doi:10.1111/febs.13472 · Cited by 113 · see citing works

Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer

Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 118 · see citing works

The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy

Wang, C., Kong, L.-Z., Kim, S., Lee, S., Oh, S., Jo, S., Jang, I.-H., & Kim, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810412 · Cited by 112 · see citing works

Novel biological insights in T-cell acute lymphoblastic leukemia

Durinck, K., Goossens, S., Peirs, S., Wallaert, A., Loocke, W. V., Matthijssens, F., Pieters, T., Milani, G., Lammens, T., Rondou, P., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.017 · Cited by 109 · see citing works

Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition

Habets, R., de Bock, C. E., Serneels, L., Lodewijckx, I., Verbeke, D., Nittner, D., Narlawar, R., Demeyer, S., Dooley, J., Liston, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6246 · Cited by 106 · see citing works

BH3-mimetics: recent developments in cancer therapy

Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 101 · see citing works

Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules

Yap, J. L., Chen, L., Lanning, M. E., & Fletcher, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01888 · Cited by 99 · see citing works

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia

Bassan, R., Bourquin, J., DeAngelo, D. J., & Chiaretti, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3648 · Cited by 97 · see citing works

T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness

Bardelli, V., Arniani, S., Pierini, V., Giacomo, D. D., Pierini, T., Gorello, P., Mecucci, C., & Starza, R. L. (2021) · Genes · doi:10.3390/genes12081118 · Cited by 95 · see citing works

B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy

Alam, M., Ali, S., Mohammad, T., Hasan, G. M., Yadav, D. K., & Hassan, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910442 · Cited by 97 · see citing works

IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update

Oliveira, M. L., Akkapeddi, P., Ribeiro, D., Melão, A., & Barata, J. T. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.09.012 · Cited by 92 · see citing works

Relapsed T Cell ALL: Current Approaches and New Directions

McMahon, C. M., & Luger, S. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00501-3 · Cited by 87 · see citing works

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.276 · Cited by 86 · see citing works

Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside

Vela, L., & Marzo, I. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.014 · Cited by 86 · see citing works

Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine

Morita, K., Jain, N., Kantarjian, H. M., Takahashi, K., Fang, H., Konopleva, M. Y., Hussein, S. E., Wang, F., Short, N. J., Maiti, A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26144 · Cited by 84 · see citing works

The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia

Lato, M., Przysucha, A., GROSMAN, S., Zawitkowska, J., & Lejman, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094502 · Cited by 84 · see citing works

Targeting Cancer Cell Mitochondria as a Therapeutic Approach: Recent Updates

Cui, Q., Wen, S., & Huang, P. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0011 · Cited by 80 · see citing works

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

Leonard, J. T., Rowley, J., Eide, C. A., Traer, E. A., Hayes‐Lattin, B., Loriaux, M., Spurgeon, S. E. F., Druker, B. J., Tyner, J. W., & Chang, B. H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5309 · Cited by 81 · see citing works

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

Chiron, D., Dousset, C., Brosseau, C., Touzeau, C., Maïga, S., Moreau, P., Pellat‐Deceunynck, C., Gouill, S. L., & Amiot, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3275 · Cited by 80 · see citing works

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL

Kampen, K. R., Sulima, S. O., Verbelen, B., Girardi, T., Vereecke, S., Rinaldi, G., Verbeeck, J., de Beeck, J. O., Uyttebroeck, A., Meijerink, J. P. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0176-z · Cited by 76 · see citing works

MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies

Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Liefwalker, D. F., Horton, C. E., Mosley, A. R., Liebersbach, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16447-7 · Cited by 74 · see citing works

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

Laszlo, G. S., Gudgeon, C. J., Harrington, K. H., & Walter, R. B. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.68 · Cited by 75 · see citing works

MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint

Smith, B. A. H., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinage, J. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215376120 · Cited by 73 · see citing works

Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function

Lindamulage, I. K. S., Vu, H.-Y. T., Karthikeyan, C., Knockleby, J., Lee, Y.-F., Trivedi, P., & Lee, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-10972-0 · Cited by 72 · see citing works

Selective targeting of antiapoptotic BCL‐2 proteins in cancer

Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 71 · see citing works

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia

Peirs, S., Frismantas, V., Matthijssens, F., Loocke, W. V., Pieters, T., Vandamme, N., Lintermans, B., Dobay, M. P., Berx, G., Poppe, B. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.10 · Cited by 70 · see citing works

Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia

Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 70 · see citing works

Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study

Candoni, A., Lazzarotto, D., Ferrara, F., Curti, A., Lussana, F., Papayannidis, C., Principe, M. I. D., Bonifacio, M., Mosna, F., Delia, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25957 · Cited by 69 · see citing works

Computer-Aided Drug Discovery for Undruggable Targets

Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 69 · see citing works

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Gibson, A., Trabal, A., McCall, D. C., Khazal, S. J., Toepfer, L., Bell, D., Roth, M. E., Mahadeo, K. M., Núnêz, C., Short, N. J., et al. (2021) · Cancers · doi:10.3390/cancers14010150 · Cited by 68 · see citing works

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling

Seyfried, F., Demir, S., Hörl, R. L., Stirnweiß, F. U., Ryan, J. A., Scheffold, A., Villalobos-Ortiz, M., Boldrin, E., Zinngrebe, J., Enzenmüller, S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1801-0 · Cited by 64 · see citing works

How I treat adults with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia

Frey, N. V., & Luger, S. M. (2015) · Blood · doi:10.1182/blood-2014-09-551937 · Cited by 65 · see citing works

Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies

Place, A. E., Goldsmith, K. C., Bourquin, J., Loh, M. L., Gore, L., Morgenstern, D. A., Sanzgiri, Y. D., Hoffman, D., Zhou, Y. Y., Ross, J. A., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0121 · Cited by 64 · see citing works

Enzyme-cleavable polymeric micelles for the intracellular delivery of proapoptotic peptides

Kern, H. B., Srinivasan, S., Convertine, A. J., Hockenbery, D., Press, O. W., & Stayton, P. S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01178 · Cited by 63 · see citing works

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

Lonetti, A., Cappellini, A., Bertaina, A., Locatelli, F., Pession, A., Buontempo, F., Evangelisti, C., Evangelisti, C., Orsini, E., Zambonin, L., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0344-4 · Cited by 62 · see citing works

Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects

Opydo‐Chanek, M., Gonzalo, Ó., & Marzo, I. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.006 · Cited by 60 · see citing works

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients

Cyrenne, B. M., Lewis, J. M., Weed, J. G., Carlson, K. R., Mirza, F. N., Foss, F. M., & Girardi, M. (2017) · Blood · doi:10.1182/blood-2017-06-792150 · Cited by 60 · see citing works

Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling

Gu, L., Surolia, R., Larson‐Casey, J. L., He, C., Davis, D., Kang, J., Antony, V. B., & Carter, A. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00840-w · Cited by 57 · see citing works

SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival

Su, H., Hu, J., Huang, L., Yang, Y., Thénoz, M., Kuchmiy, A. A., Hu, Y., Li, P., Feng, H., Zhou, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06523-4 · Cited by 56 · see citing works

Interplay between Mitochondrial Metabolism and Cellular Redox State Dictates Cancer Cell Survival

Foo, B. J.-A., Eu, J. Q., Hirpara, J. L., & Pervaiz, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1341604 · Cited by 55 · see citing works

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 54 · see citing works

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Silva, A., Almeida, A. R. M., Cachucho, A., Neto, J. L., Demeyer, S., Matos, M., Hogan, T. V., Li, Y., Meijerink, J. P. P., Cools, J., et al. (2021) · Blood · doi:10.1182/blood.2019000553 · Cited by 54 · see citing works

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0241-7 · Cited by 54 · see citing works

Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults

Patel, A. A., Thomas, J., Rojek, A. E., & Stock, W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00757-5 · Cited by 52 · see citing works

First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Numan, Y., Alfayez, M., Maiti, A., Alvarado, Y., Jabbour, E. J., Ferrajoli, A., Konoplev, S. N., Kantarjian, H. M., & Bose, P. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00127 · Cited by 51 · see citing works

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

Akahane, K., Sanda, T., Mansour, M. R., Radimerski, T., DeAngelo, D. J., Weinstock, D. M., & Look, A. T. (2015) · Leukemia · doi:10.1038/leu.2015.222 · Cited by 49 · see citing works

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma

Luo, Q., Pan, W., Zhou, S., Wang, G., Yi, H., Zhang, L., Yan, X., Yuan, L., Liu, Z., Wang, J., et al. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504020x15825405463920 · Cited by 48 · see citing works

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia

Farhadfar, N., Li, Y., May, W. S., & Adams, C. B. (2020) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2019.10.002 · Cited by 49 · see citing works

Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases

Xu, W., Chen, S., Wang, X., Tanaka, S., Onda, K., Sugiyama, K., Yamada, H., & Hirano, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107659 · Cited by 49 · see citing works

The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

McBride, A., Houtmann, S., Wilde, L. R., Vigil, C. E., Eischen, C. M., Kasner, M. T., & Palmisiano, N. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00192 · Cited by 48 · see citing works

Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol

Olivas-Aguirre, M., Torres-López, L., Pottosin, I. I., & Dobrovinskaya, O. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617937 · Cited by 47 · see citing works

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Zhu, Z., Liu, J., Yang, C., Zhao, M., & Xiong, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1627-9 · Cited by 45 · see citing works

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Laukkanen, S., Veloso, A. B., Yan, C., Oksa, L., Alpert, E. J., Do, D., Hyvärinen, N., McCarthy, K. M., Adhikari, A., Yang, Q., et al. (2022) · Blood · doi:10.1182/blood.2021015106 · Cited by 46 · see citing works

The path to venetoclax resistance is paved with mutations, metabolism, and more

Sullivan, G. P., Flanagan, L., Rodrigues, D. A., & Chonghaile, T. N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo6891 · Cited by 45 · see citing works

Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia

Chiaretti, S., Gianfelici, V., O'Brien, S. M., & Mullighan, C. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156628 · Cited by 45 · see citing works

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations

Senkevitch, E., Li, W., Hixon, J. A., Andrews, C., Cramer, S. D., Pauly, G. T., Back, T. C., Czarra, K., & Durum, S. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25194 · Cited by 44 · see citing works

Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells

Xie, S. P., Jiang, H., Zhai, X., Fan, W. Q., Wang, S., Ding, J., & Chen, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.49 · Cited by 44 · see citing works

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia

Starza, R. L., Cambò, B., Pierini, A., Bornhauser, B. C., Montanaro, A., Bourquin, J., Mecucci, C., & Roti, G. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00172 · Cited by 43 · see citing works

Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia

Tan, T. K., Zhang, C., & Sanda, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2518-z · Cited by 40 · see citing works

Mitochondria as emerging targets for therapies against T cell acute lymphoblastic leukemia

Olivas-Aguirre, M., Pottosin, I. I., & Dobrovinskaya, O. R. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5vmr0818-330rr · Cited by 42 · see citing works

Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia

Rashkovan, M., Alberó, R., Gianni, F., Perez-Duran, P., Miller, H. I., Mackey, A. L., Paietta, E. M., Tallman, M. S., Rowe, J. M., Litzow, M. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0551 · Cited by 42 · see citing works

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant

Rahmat, L. T., Nguyen, A., Abdulhaq, H., Prakash, S., Logan, A. C., & Mannis, G. N. (2018) · Case Reports in Hematology · doi:10.1155/2018/6092646 · Cited by 41 · see citing works

Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation

Gachet, S., El-Chaar, T., Avran, D., Genescà, E., Catez, F., Quentin, S., Delord, M., Thérizols, G., Briot, D., Meunier, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0831 · Cited by 41 · see citing works

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia

Ricciardi, M. R., Mirabilii, S., Licchetta, R., Piedimonte, M., & Tafuri, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.002 · Cited by 40 · see citing works

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Short, N. J., Jabbour, E. J., Jain, N., Senapati, J., Nasr, L. F., Haddad, F., Li, Z., Hsiao, Y.-C., Yang, J. J. J., Pemmaraju, N., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012231 · Cited by 38 · see citing works

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

Aumann, S., Shaulov, A., Haran, A., Even‐Zohar, N. G., Vainstein, V., & Nachmias, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810957 · Cited by 37 · see citing works

Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia

Akahane, K., Li, Z., Etchin, J., Berezovskaya, A., Gjini, E., Masse, C. E., Miao, W., Rocnik, J. L., Kapeller, R., Greenwood, J. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14563 · Cited by 37 · see citing works

The promise of Janus kinase inhibitors in the treatment of hematological malignancies

Senkevitch, E., & Durum, S. K. (2016) · Cytokine · doi:10.1016/j.cyto.2016.10.012 · Cited by 37 · see citing works

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines

Koss, B. S., Ryan, J. A., Budhraja, A., Szarama, K. B., Yang, X., Bathina, M., Cardone, M. H., Nikolovska‐Coleska, Z., Letai, A. G., & Opferman, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.7204 · Cited by 36 · see citing works

Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia

Huang, F., Yu, S., & Li, C. (2021) · Cancer Control · doi:10.1177/10732748211019138 · Cited by 34 · see citing works

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system

Bornschein, S., Demeyer, S., Stirparo, R., Gielen, O., Vicente, C., Geerdens, E., Ghesquière, B., Aerts, S., Cools, J., & de Bock, C. E. (2017) · Leukemia · doi:10.1038/leu.2017.328 · Cited by 32 · see citing works

Bcl-2 family inhibitors sensitize human cancer models to therapy

Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 35 · see citing works

Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis

Tian, B., Li, F., Li, R., Hu, X., Lai, T., Lu, J., Zhao, Y. F., Du, Y., Liang, Z., Zhu, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.020 · Cited by 31 · see citing works

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia

Mansour, M. R., He, S., Li, Z., Lobbardi, R., Abraham, B. J., Hug, C. B., Rahman, S., León, T. E., Kuang, Y., Zimmerman, M. W., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170484 · Cited by 31 · see citing works

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

Smedt, R. D., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., Goossens, S., Lammens, T., Roy, N. V., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.199257 · Cited by 31 · see citing works

Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison

Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30 · see citing works

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia

Luskin, M. R., Shimony, S. O., Keating, J. H., Winer, E. S., Garcia, J. S., Stone, R. M., Jabbour, E. J., Flamand, Y., Stevenson, K. E., Ryan, J. A., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014405 · Cited by 30 · see citing works

Therapeutic opportunities based on caspase modulation

Fulda, S. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.12.008 · Cited by 30 · see citing works

Targeting steroid resistance in T-cell acute lymphoblastic leukemia

Smedt, R. D., Morscio, J., Goossens, S., & Vlierberghe, P. V. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100591 · Cited by 30 · see citing works

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J. A., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B. L., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 276 · see citing works

Characterizing the role of BCL-2 family members as targets for anti-cancer therapy

Fortner, C. (2026) · doi:10.18725/oparu-60666

Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL

Fortner, C., Niedermayer, A., Bäuerle, M. M., Wichert, M. C., Braun, C. J., Debatin, K., Vogler, M., Meyer, L. H., & Seyfried, F. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08698-x · Cited by 1 · see citing works

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Shah, K., & Kazi, J. U. (2019) · Blood · doi:10.1182/blood-2019-129823

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Fortner, C., Wichert, M. C., Niedermayer, A., Debatin, K., Meyer, L. H., & Seyfried, F. (2023) · Blood · doi:10.1182/blood-2023-177613